Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.

ABSTRACT:

Aims

The aims of the present study were to compare the pharmacokinetics of oseltamivir and its active antiviral metabolite oseltamivir carboxylate in obese and non-obese individuals and to determine the effect of obesity on the pharmacokinetic properties of oseltamivir and oseltamivir carboxylate.

Methods

The population pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated in 12 obese [body mass index (BMI) ≥30 kg m(-2) ) and 12 non-obese (BMI <30 kg m(-2) ) Thai adult volunteers receiving a standard dose of 75 mg and a double dose of 150 mg in a randomized sequence. Concentration-time data were collected and analysed using nonlinear mixed-effects modelling.

Results

The pharmacokinetics of oseltamivir and oseltamivir carboxylate were des

SUBMITTER: Chairat K 

PROVIDER: S-EPMC4876175 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature